GLYC News and Press, GlycoMimetics Inc. From 08/04/21

Mrs. King, the company’s founding CEO, will remain a Director and advisor to support transition GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and ...

GlycoMimetics (GLYC) announces that the first patient was treated in an early-stage study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine ((LDAC)) in patients with treated secondary acute myeloid leukemia ((ts-AML)).The ...

Trial to study uproleselan combination in patients with high-risk treated secondary AML GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company’s lead drug candidate, uproleselan, a...

GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $1.96. So far today approximately 203,000 shares have been exchanged, as compared to an average 30-day volume of 663,000 shares. GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discove...

Shares of GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $2.02. This new low was reached on below average trading volume as 203,000 shares traded hands, while the average 30-day volume is approximately 684,000 shares. Potential upside of 1.8% exists for GlycoMimeti...

Shares of GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $2.02. This new low was reached on below average trading volume as 203,000 shares traded hands, while the average 30-day volume is approximately 684,000 shares. GlycoMimetics Inc. (NASDAQ:GLYC) has potential ...

GlycoMimetics (GLYC) announces that dosing has started in the study of a combination of the company's uproleselan in treating certain patients with acute myeloid leukemia ((AML)).The investigator-sponsored trial by University of California ((UC)) Davis Comprehensive Cancer Center is eval...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit pat...

ToughBuilt Industries (TBLT) -29% ToughBuilt Industries launches $40M direct offeringAerpio Pharmaceuticals (ARPO) -8%.Nova LifeStyle (NVFY) -9%.UTStarcom Holdings (UTSI) -7%.GlycoMimetics (GLYC) -6%.Digital Brands Group (DBGI) -5%. For further details see: Aerpio Pharmaceutic...